Immunotherapy News and Research RSS Feed - Immunotherapy News and Research

Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.
New guidelines help allergist steer patient out of yellow zone and back into green

New guidelines help allergist steer patient out of yellow zone and back into green

If you have asthma, you may have an asthma action plan with a "stoplight system" to help you recognize and respond to changes and understand when symptoms are getting worse and need more attention. [More]
Tips from ACAAI to help kids enjoy healthy, symptom-free days in classroom

Tips from ACAAI to help kids enjoy healthy, symptom-free days in classroom

Your kids may be enjoying the lazy days of summer, but if they have asthma, allergies, or both, they need to be prepared for back-to-school. And so do their classrooms. More than 10 million kids under age 18 have asthma, and 11 percent suffer from respiratory allergies. About 6 percent have also been diagnosed with food allergies. [More]
EMA CHMP adopts positive opinion for Janssen’s IMBRUVICA to treat CLL and MCL

EMA CHMP adopts positive opinion for Janssen’s IMBRUVICA to treat CLL and MCL

Janssen-Cilag International NV announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the granting of a marketing authorisation for IMBRUVICA (ibrutinib) in the European Union. [More]
EMA recommends full marketing approval for IMBRUVICA in the European Union

EMA recommends full marketing approval for IMBRUVICA in the European Union

Pharmacyclics, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending the granting of full marketing approval for IMBRUVICA (ibrutinib) in the European Union. [More]
Advaxis, MedImmune team up for immuno-oncology clinical trial

Advaxis, MedImmune team up for immuno-oncology clinical trial

Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca. [More]
New molecules and biopharmaceuticals enhance patient's immune response against tumors

New molecules and biopharmaceuticals enhance patient's immune response against tumors

Researchers at the University of Arkansas have been awarded $1.5 million from the National Cancer Institute at the National Institutes of Health to develop new molecules and biopharmaceuticals that enhance a patient's immune response against tumors. [More]
New molecular analysis tool to detect targets for immunotherapy in early-stage breast cancers

New molecular analysis tool to detect targets for immunotherapy in early-stage breast cancers

Yale Cancer Center researchers used a new molecular analysis tool to accurately detect the level of an important target for immunotherapy in early-stage breast cancers. [More]
Researchers find viable immunotherapy option for HIV-1 using fossil virus

Researchers find viable immunotherapy option for HIV-1 using fossil virus

The road to finding a cure for HIV-1 is not without obstacles. However, thanks to cutting-edge research by Douglas Nixon, M.D., Ph.D., and colleagues, performed at the George Washington University (GW), Oregon Health & Science University, the University of Rochester, and UC San Francisco, the scientific community is one step closer to finding a viable immunotherapy option for HIV-1, using an immune attack against a fossil virus buried in the genome. [More]
First publication describing use of CytoSorb during cardiac surgery

First publication describing use of CytoSorb during cardiac surgery

CytoSorbents Corporation, a critical care immunotherapy company commercializing its CytoSorb® cytokine adsorber in multiple countries worldwide, announced the PDF availability of the first publication describing the use of CytoSorb® intra-operatively during cardiac surgery at the Ludwig Maximilian University of Munich Hospital - Grosshadern Campus, in Germany. [More]
Scientist fights extremely aggressive and difficult-to-treat form of breast cancer

Scientist fights extremely aggressive and difficult-to-treat form of breast cancer

Biomedical scientist Kimberly L. Koss, PhD, is fighting an extremely aggressive and difficult-to-treat form of breast cancer. [More]
Lilly, Immunocore enter into co-discovery and co-development collaboration to develop cancer therapies

Lilly, Immunocore enter into co-discovery and co-development collaboration to develop cancer therapies

Eli Lilly and Company and Immunocore Limited today announced they have entered into a co-discovery and co-development collaboration to research and potentially develop novel T cell-based cancer therapies. [More]
Engineering single-celled parasite in cat's intestine as cancer vaccine

Engineering single-celled parasite in cat's intestine as cancer vaccine

Toxoplasma gondii (T. gondii) is a single-celled parasite that is happiest in a cat's intestines, but it can live in any warm blooded animal. Found worldwide, T. gondii affects about one-third of the world's population, 60 million of which are Americans. [More]
BAI and Novartis determine whether investigational drugs can prevent symptoms of Alzheimer's

BAI and Novartis determine whether investigational drugs can prevent symptoms of Alzheimer's

Researchers from the Banner Alzheimer's Institute (BAI) today announced a partnership with Novartis in a pioneering medical trial to determine whether two investigational anti-amyloid drugs-an active immunotherapy and an oral medication-can prevent or delay the emergence of symptoms of Alzheimer's in people at particularly high risk for developing the disease at older ages. [More]
Lung cancer and melanoma funders form first-ever research collaboration

Lung cancer and melanoma funders form first-ever research collaboration

LUNGevity Foundation today announced a partnership with the Lung Cancer Research Foundation and Melanoma Research Alliance to co-fund new innovative research on PD-1 inhibitor treatment options for both non-small cell lung cancer (NSCLC) and metastatic melanoma (MM) patients with brain metastases. [More]
New gene therapy may be effective for fighting fungal infections in cancer patients

New gene therapy may be effective for fighting fungal infections in cancer patients

Sleeping Beauty and fungal infections - not two items one would normally associate together, but for immunocompromised cancer patients they may prove to be a helpful combination. [More]
Novel cancer immunotherapy for dogs could benefit humans as well

Novel cancer immunotherapy for dogs could benefit humans as well

As in humans, cancers in dogs have complex causes. The interaction of the environment, food, and genetic disposition are the most well known factors. Today nearly all methods of human medicine are basically available for dogs with cancer, but this was not true of cancer immunotherapy so far. [More]
FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL). [More]
Penn’s immunotherapy receives FDA's Breakthrough Therapy designation for ALL treatment

Penn’s immunotherapy receives FDA's Breakthrough Therapy designation for ALL treatment

A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL). [More]
TxCell announces launch of POSITIVE project to automate manufacturing process for Ovasave

TxCell announces launch of POSITIVE project to automate manufacturing process for Ovasave

TxCell SA, a biotech developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, announces today the launch of, and funding awarded to, the POSITIVE project in collaboration with the Gene and Cell therapy Unit (UTCG) developing new antiviral cell-based immunotherapies and Biosafe, a Swiss private company, a developer of innovative solutions for cell processing. [More]
New collaborative fundraising effort focuses on AYA cancer

New collaborative fundraising effort focuses on AYA cancer

Leaders from Case Western Reserve University and University Hospitals this evening announced a new collaborative fundraising effort focused on Adolescent and Young Adult (AYA) cancer. [More]